Table 2.
Baseline characteristics of study cohort
| Variable | Cases (n = 24) | Controls (n = 24) |
|---|---|---|
| Age, years [mean (SD)] | 52.2 (8.4) | 52.6 (7.8) |
| Female, n (%) | (21) | (21) |
| Black race, n (%) | (50) | (50) |
| Tobacco use (current or former), n (%) | (75) | (55) |
| Diabetes, n (%) | (13) | (4) |
| Hypertension, n (%) | (54) | (54) |
| Systolic blood pressure, mmHg [mean (SD)] | 137.6 (16.0) | 137.4 (19.2) |
| Diastolic blood pressure, mmHg [mean (SD)] | 81.6 (11.8) | 83.8 (11.4) |
| Body mass index, kg/m2 [mean(SD)] | 26.5 (4.0) | 26.8 (4.9) |
| Proximal CD4 count, cells/uL [median (IQR)] | (214,654) | (285,762) |
| ART regimen at time of specimen collection, n (%) PI-based | (63) | (42) |
| NNRTI-based | (33) | (54) |
| INSTI-based | 0 | 0 |
| Other | (4) | (4) |
| AZT, DDI or D4T backbone | (50) | (25) |
| ABC backbone | (21) | (17) |
| Any PI exposure | (67) | (63) |
IQR interquartile range, SD standard deviation, ABC abacavir, ART antiretroviral therapy, AZT azidothymidine, DDI didanosine, D4T stavudine, INSTI integrase strand transfer inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor